Synthetic toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses

Journal of Virology

Volumn 89, Issue 6, 2015, Pages 3221-3235

  Goff, Peter H ^a   Hayashi, Tomoko ^b   Martínez Gil, Luis ^a   Corr, Maripat ^c   Crain, Brian ^b   Yao, Shiyin ^b   Cottam, Howard B ^b   Chan, Michael ^b   Ramos, Irene ^a   Eggink, Dirk ^a   Heshmati, Mitra ^a   Krammer, Florian ^a   Messer, Karen ^b   Pu, Minya ^b   Fernandez Sesma, Ana ^a   Palese, Peter ^a   Carson, Dennis A ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G1; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; IV 270; IZ 105; OVALBUMIN; RECOMBINANT PROTEIN; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG; VIRUS ANTIGEN; LIGAND; TLR4 PROTEIN, HUMAN; TLR7 PROTEIN, HUMAN; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; AVIAN INFLUENZA; CELL MATURATION; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFECTION PREVENTION; INFLUENZA; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; AGONISTS; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CROSS PROTECTION; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); SYNTHESIS; VIROLOGY;

ANTIDESMA PLATYPHYLLUM; MURINAE; ORTHOMYXOVIRIDAE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, VIRAL; CROSS PROTECTION; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LIGANDS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; TH1 CELLS; TH2 CELLS; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 7;

EID: 84923172337     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03337-14     Document Type: Article

References (58)

1. Ohmit SE, Petrie JG, Malosh RE, Cowling BJ, Thompson MG, Shay DK, Monto AS. 2013. Influenza vaccine effectiveness in the community and the household. Clin Infect Dis 56:1363-1369. http://dx.doi.org/10 .1093/cid/cit060.
2. Thompson WW, Comanor L, Shay DK. 2006. Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease. J Infect Dis 194:S82-S91. http://dx.doi.org/10.1086/507558.
3. Izurieta HS, Thompson WW, Kramarz P, Shay DK, Davis RL, DeStefano F, Black S, Shinefield H, Fukuda K. 2000. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 342:232-239. http://dx.doi.org/10.1056/NEJM2000012734 20402.
4. Smith GJ, Bahl J, Vijaykrishna D, Zhang J, Poon LL, Chen H, Webster RG, Peiris JS, Guan Y. 2009. Dating the emergence of pandemic influenza viruses. Proc Natl Acad Sci U S A 106:11709-11712. http://dx.doi.org/10 .1073/pnas.0904991106.
5. Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, Rotthoff J, Boulton M, Victor JC. 2009. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 361:1260-1267. http://dx.doi.org/10.1056/NEJMoa0808652.
6. Petrie JG, Ohmit SE, Johnson E, Cross RT, Monto AS. 2011. Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. J Infect Dis 203:1309-1315. http://dx.doi.org/10.1093/infdis/jir015.
7. Cox RJ. 2013. Correlates of protection to influenza virus, where do we go from here? Hum Vaccin Immunother 9:405-408. http://dx.doi.org/10 .4161/hv.22908.
8. Hannoun C. 2013. The evolving history of influenza viruses and influenza vaccines. Expert Rev Vaccines 12:1085-1094. http://dx.doi.org/10.1586/14760584.2013.824709.
9. Krammer F, Palese P. 2014. Universal influenza virus vaccines: need for clinical trials. Nat Immunol 15:3-5. http://dx.doi.org/10.1038/nri3797.
10. Krammer F, Palese P. 2013. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol 3:521-530. http://dx.doi.org/10 .1016/j.coviro.2013.07.007.
11. Krammer F, Palese P, Steel J. 2015. Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. Curr Top Microbiol Immunol 386:301-321. http://dx.doi.org/10.1007/82_2014_408.
12. Koff WC, Burton DR, Johnson PR, Walker BD, King CR, Nabel GJ, Ahmed R, Bhan MK, Plotkin SA. 2013. Accelerating next-generation vaccine development for global disease prevention. Science 340:1232910. http://dx.doi.org/10.1126/science.1232910.
13. Reed SG, Orr MT, Fox CB. 2013. Key roles of adjuvants in modern vaccines. Nat Med 19:1597-1608. http://dx.doi.org/10.1038/nm.3409.
14. Chan M, Hayashi T, Mathewson RD, Nour A, Hayashi Y, Yao S, Tawatao RI, Crain B, Tsigelny IF, Kouznetsova VL, Messer K, Pu M, Corr M, Carson DA, Cottam HB. 2013. Identification of substituted pyrimido[5,4-b]indoles as selective Toll-like receptor 4 ligands. J Med Chem 56:4206-4223. http://dx.doi.org/10.1021/jm301694x.
15. Pu M, Hayashi T, Cottam H, Mulvaney J, Arkin M, Corr M, Carson D, Messer K. 2012. Analysis of high-throughput screening assays using cluster enrichment. Stat Med 31:4175-4189. http://dx.doi.org/10.1002/sim .5455.
16. Angelo MG, Taylor S, Struyf F, Tavares Da Silva F, Arellano F, David MP, Dubin G, Rosillon D, Baril L. 2014. Strategies for continuous evaluation of the benefit-risk profile of HPV-16/18-AS04-adjuvanted vaccine. Expert Rev Vaccines http://dx.doi.org/10.1586/14760584.2014 .959931.
17. Wu CC, Crain B, Yao S, Sabet M, Lao FS, Tawatao RI, Chan M, Smee DF, Julander JG, Cottam HB, Guiney DG, Corr M, Carson DA, Hayashi T. 2014. Innate immune protection against infectious diseases by pulmonary administration of a phospholipid-conjugated TLR7 ligand. J Innate Immun 6:315-324. http://dx.doi.org/10.1159/000355217.
18. Hayashi T, Chan M, Norton JT, Wu CC, Yao S, Cottam HB, Tawatao RI, Corr M, Carson DA, Daniels GA. 2011. Additive melanoma suppression with intralesional phospholipid-conjugated TLR7 agonists and systemic IL-2. Melanoma Res 21:66-75. http://dx.doi.org/10.1097/CMR .0b013e328340ce6c.
19. Chan M, Hayashi T, Kuy CS, Gray CS, Wu CC, Corr M, Wrasidlo W, Cottam HB, Carson DA. 2009. Synthesis and immunological characterization of Toll-like receptor 7 agonistic conjugates. Bioconjug Chem 20: 1194-1200. http://dx.doi.org/10.1021/bc900054q.
20. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I. 2009. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 361:2424-2435. http://dx.doi.org/10 .1056/NEJMoa0907650.
21. Krammer F, Pica N, Hai R, Margine I, Palese P. 2013. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol 87:6542-6550. http://dx.doi.org/10.1128/JVI.00641-13.
22. Goff PH, Eggink D, Seibert CW, Hai R, Martinez-Gil L, Krammer F, Palese P. 2013. Adjuvants and immunization strategies to induce influenza virus hemagglutinin stalk antibodies. PLoS One 8:e79194. http://dx .doi.org/10.1371/journal.pone.0079194.
23. Hai R, Krammer F, Tan GS, Pica N, Eggink D, Maamary J, Margine I, Albrecht RA, Palese P. 2012. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J Virol 86:5774-5781. http://dx.doi.org/10.1128/JVI.00137-12.
24. Margine I, Krammer F, Hai R, Heaton NS, Tan GS, Andrews SA, Runstadler JA, Wilson PC, Albrecht RA, Garcia-Sastre A, Palese P. 2013. Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J Virol 87:10435-10446. http://dx.doi .org/10.1128/JVI.01715-13.
25. Ahmed SS, Schur PH, MacDonald NE, Steinman L. 2014. Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. J Autoimmun 50:1-11. http://dx.doi.org/10.1016/j.jaut.2014.01.033.
26. Fox CB, Haensler J. 2013. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Rev Vaccines 12: 747-758. http://dx.doi.org/10.1586/14760584.2013.811188.
27. Ahmed SS, Plotkin SA, Black S, Coffman RL. 2011. Assessing the safety of adjuvanted vaccines. Sci Transl Med 3:93rv92. http://dx.doi.org/10 .1126/scitranslmed.3002302.
28. Hoebe K, Du X, Georgel P, Janssen E, Tabeta K, Kim S, Goode J, Lin P, Mann N, Mudd S, Crozat K, Sovath S, Han J, Beutler B. 2003. Identification of Lps2 as a key transducer of MyD88-independent TIR signalling. Nature 424:743-748. http://dx.doi.org/10.1038/nature01889.
29. Krammer F, Margine I, Tan GS, Pica N, Krause JC, Palese P. 2012. A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates. PLoS One 7:e43603. http://dx.doi.org/10.1371/journal.pone .0043603.
30. Saitou N, Nei M. 1987. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 4:406-425.
31. Felsenstein J. 1985. Confidence limits on phylogenies: an approach using the bootstrap source. Evolution 39:783-791. http://dx.doi.org/10.2307/2408678.
32. Zuckerkandl E, Pauling L. 1965. Evolutionary divergence and convergence in proteins. Academic Press, New York, NY.
33. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. 2011. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol 28:2731-2739. http://dx.doi.org/10.1093/molbev/msr121.
34. Wu CC, Hayashi T, Takabayashi K, Sabet M, Smee DF, Guiney DD, Cottam HB, Carson DA. 2007. Immunotherapeutic activity of a conjugate of a Toll-like receptor 7 ligand. Proc Natl Acad Sci U S A 104:3990-3995. http://dx.doi.org/10.1073/pnas.0611624104.
35. Fernandez-Sesma A, Marukian S, Ebersole BJ, Kaminski D, Park MS, Yuen T, Sealfon SC, Garcia-Sastre A, Moran TM. 2006. Influenza virus evades innate and adaptive immunity via the NS1 protein. J Virol 80: 6295-6304. http://dx.doi.org/10.1128/JVI.02381-05.
36. Ramos I, Bernal-Rubio D, Durham N, Belicha-Villanueva A, Lowen AC, Steel J, Fernandez-Sesma A. 2011. Effects of receptor binding specificity of avian influenza virus on the human innate immune response. J Virol 85:4421-4431. http://dx.doi.org/10.1128/JVI.02356-10.
37. Webster R, Cox N, Stöhr K. 2002. WHO manual on animal influenza diagnosis and surveillance. WHO/CDS/CSR/NCS/2002.5.WHO,Geneva, Switzerland.
38. Bartlett MS. 1937. Properties of sufficiency and statistical tests. Proc R Soc Lond A 160:268-282. http://dx.doi.org/10.1098/rspa.1937.0109.
39. Konietschke F, Hothorn LA, Brunner E. 2012. Rank-based multiple test procedures and simultaneous confidence intervals. Electron J Stat 6:738-759. http://dx.doi.org/10.1214/12-EJS691.
40. Kasturi SP, Skountzou I, Albrecht RA, Koutsonanos D, Hua T, Nakaya HI, Ravindran R, Stewart S, Alam M, Kwissa M, Villinger F, Murthy N, Steel J, Jacob J, Hogan RJ, Garcia-Sastre A, Compans R, Pulendran B. 2011. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470:543-547. http://dx.doi.org/10.1038/nature09737.
41. Fox CB, Sivananthan SJ, Duthie MS, Vergara J, Guderian JA, Moon E, Coblentz D, Reed SG, Carter D. 2014. A nanoliposome delivery system to synergistically trigger TLR4ANDTLR7. J Nanobiotechnology 12:17. http://dx.doi.org/10.1186/1477-3155-12-17.
42. Suet Ting Tan R, Lin B, Liu Q, Tucker-Kellogg L, Ho B, Leung BP, Ling Ding J. 2013. The synergy in cytokine production through MyD88-TRIF pathways is co-ordinated with ERK phosphorylation in macrophages. Immunol Cell Biol 91:377-387. http://dx.doi.org/10.1038/icb.2013.13.
43. Hoebe K, Beutler B. 2004. LPS, dsRNA and the interferon bridge to adaptive immune responses: Trif, Tram, and other TIR adaptor proteins. J Endotoxin Res 10:130-136. http://dx.doi.org/10.1177/09680519040100 021001.
44. Gandhapudi SK, Chilton PM, Mitchell TC. 2013. TRIF is required for TLR4 mediated adjuvant effects on T cell clonal expansion. PLoS One 8:e56855. http://dx.doi.org/10.1371/journal.pone.0056855.
45. Clegg CH, Roque R, Hoeven NV, Perrone L, Baldwin SL, Rininger JA, Bowen RA, Reed SG. 2012. Adjuvant solution for pandemic influenza vaccine production. Proc Natl Acad Sci U S A 109:17585-17590. http://dx .doi.org/10.1073/pnas.1207308109.
46. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. 2010. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 28:1740-1745. http://dx.doi.org/10.1016/j.vaccine.2009.12.014.
47. Moran TM, Park H, Fernandez-Sesma A, Schulman JL. 1999. Th2 responses to inactivated influenza virus can be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection. J Infect Dis 180:579-585. http://dx.doi.org/10.1086/314952.
48. Reference deleted.
49. Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, Xu L, Andersen H, Rao S, Tumpey TM, Yang ZY, Nabel GJ. 2010. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329:1060-1064. http://dx.doi.org/10.1126/science.1192517.
50. Pica N, Hai R, Krammer F, Wang TT, Maamary J, Eggink D, Tan GS, Krause JC, Moran T, Stein CR, Banach D, Wrammert J, Belshe RB, Garcia-Sastre A, Palese P. 2012. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad SciUSA109:2573-2578. http://dx .doi.org/10.1073/pnas.1200039109.
51. Wang TT, Tan GS, Hai R, Pica N, Ngai L, Ekiert DC, Wilson IA, Garcia-Sastre A, Moran TM, Palese P. 2010. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad SciUSA107:18979-18984. http://dx.doi.org/10.1073/pnas.1013387107.
52. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, Garcia-Sastre A, Palese P. 2010. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio 1:e00018-10. http://dx.doi.org/10.1128/mBio.00018-10.
53. Wei CJ, Yassine HM, McTamney PM, Gall JG, Whittle JR, Boyington JC, Nabel GJ. 2012. Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure. Sci Transl Med 4:147ra114. http://dx.doi.org/10.1126/scitranslmed.3004273.
54. Graves PN, Schulman JL, Young JF, Palese P. 1983. Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: Unmasking of cross-reactiveHA2determinants. J Virol 126:106-116. http://dx.doi.org/10.1016/0042-6822(83)90465-8.
55. DiLillo DJ, Tan GS, Palese P, Ravetch JV. 2014. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat Med 20:143-151. http://dx.doi.org/10.1038/nm.3443.
56. Ellebedy AH, Krammer F, Li GM, Miller MS, Chiu C, Wrammert J, Chang CY, Davis CW, McCausland M, Elbein R, Edupuganti S, Spearman P, Andrews SF, Wilson PC, Garcia-Sastre A, Mulligan MJ, Mehta AK, Palese P, Ahmed R. 2014. Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proc Natl Acad Sci U S A 111:13133-13138. http://dx.doi .org/10.1073/pnas.1414070111.
57. Nachbagauer R, Wohlbold TJ, Hirsh A, Hai R, Sjursen H, Palese P, Cox RJ, Krammer F. 2014. Induction of broadly-reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J Virol 88:13260-13268. http://dx.doi.org/10.1128/JVI.02133-14.
58. Vono M, Taccone M, Caccin P, Gallotta M, Donvito G, Falzoni S, Palmieri E, Pallaoro M, Rappuoli R, Virgilio FD, Gregorio ED, Montecucco C, Seubert A. 2013. The adjuvant MF59 induces ATP release from muscle that potentiates response to vaccination. Proc Natl Acad Sci U S A 110:21095-21100. http://dx.doi.org/10.1073/pnas.1319784110.